SEARCH:   Advanced

Blood, 1 March 2007, Vol. 109, No. 5, pp. 2156-2164. Prepublished online as a Blood First Edition Paper on October 31, 2006; DOI 10.1182/blood-2006-06-028969. This Article Full Text (PDF) Supplemental Tables All Versions of this Article: blood-2006-06-028969v1 109/5/2156    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Lamant, L. Articles by Delsol, G. Search for Related Content PubMed PubMed Citation Articles by Lamant, L. Articles by Delsol, G. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted June 13, 2006 Accepted October 5, 2006 Gene expression profiling of systemic anaplastic large cell lymphoma reveals differences depending on ALK status and two distinct morphological ALK+ subtypes Laurence Lamant, Aurelien De Reynies, Marie-Michele Duplantier, David S Rickman, Frederique Sabourdy, Sylvie Giuriato, Laurence Brugieres, Philippe Gaulard, Estelle Espinos, and Georges Delsol* INSERM U563, France Ligue Nationale contre le Cancer, France Institut Gustave Roussy, France Hopital Henri Mondor, France * Corresponding author; email: delsol.g{at}chu-toulouse.fr. Using microarray gene expression profiling, we analysed a homogeneous series of 32 cases of systemic Anaplastic Large Cell Lymphoma (ALCL) and 5 ALCL cell lines. Unsupervised analysis classified ALCL in two clusters corresponding essentially to morphological sub-groups (i.e. common type vs small cell and "mixed" variants) and clinical variables. Patients with a morphological variant of ALCL are associated with advanced stage disease. Most importantly, this group was also significantly enriched with patients who developed early relapse. Supervised analysis showed that ALK+ ALCL and ALK- ALCL have different gene expression profiles, further confirming that they are different entities. Among the most significantly differentially expressed genes between ALK+ and ALK- samples, we found BCL-6, PTPN12, C/EBPand serpinA1 genes to be overexpressed in ALK+ ALCL. This result was confirmed at the protein level for BCL-6, C/EBP and serpinA1 using tissue microarrays. The molecular signature of ALK- ALCL includes overexpression of CCR7, CNTFR, IL22 and IL21 genes but did not provide any obvious clues to the molecular mechanism underlying this tumor subtype. Once confirmed on a larger number of cases, the results of the present study could be used for clinical and therapeutic management of patients at the time of diagnosis. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. Pal, M. Janz, D. L. Galson, M. Gries, S. Li, K. Johrens, I. Anagnostopoulos, B. Dorken, M. Y. Mapara, L. Borghesi, et al. C/EBP{beta} regulates transcription factors critical for proliferation and survival of multiple myeloma cells Blood, October 29, 2009; 114(18): 3890 - 3898. [Abstract] [Full Text] [PDF] F. E. Boccalatte, C. Voena, C. Riganti, A. Bosia, L. D'Amico, L. Riera, M. Cheng, B. Ruggeri, O. N. Jensen, V. L. Goss, et al. The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL Blood, March 19, 2009; 113(12): 2776 - 2790. [Abstract] [Full Text] [PDF] A. de Reynies, G. Assie, D. S. Rickman, F. Tissier, L. Groussin, F. Rene-Corail, B. Dousset, X. Bertagna, E. Clauser, and J. Bertherat Gene Expression Profiling Reveals a New Classification of Adrenocortical Tumors and Identifies Molecular Predictors of Malignancy and Survival J. Clin. Oncol., March 1, 2009; 27(7): 1108 - 1115. [Abstract] [Full Text] [PDF] C Agostinelli, P P Piccaluga, P Went, M Rossi, A Gazzola, S Righi, T Sista, C Campidelli, P L Zinzani, B Falini, et al. Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies J. Clin. Pathol., November 1, 2008; 61(11): 1160 - 1167. [Abstract] [Full Text] [PDF] K. J. Savage, N. L. Harris, J. M. Vose, F. Ullrich, E. S. Jaffe, J. M. Connors, L. Rimsza, S. A. Pileri, M. Chhanabhai, R. D. Gascoyne, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project Blood, June 15, 2008; 111(12): 5496 - 5504. [Abstract] [Full Text] [PDF] L. de Leval and P. Gaulard Pathobiology and Molecular Profiling of Peripheral T-Cell Lymphomas Hematology, January 1, 2008; 2008(1): 272 - 279. [Abstract] [Full Text] [PDF] K. J. Savage Prognosis and Primary Therapy in Peripheral T-Cell Lymphomas Hematology, January 1, 2008; 2008(1): 280 - 288. [Abstract] [Full Text] [PDF] H. M. Amin and R. Lai Pathobiology of ALK+ anaplastic large-cell lymphoma Blood, October 1, 2007; 110(7): 2259 - 2267. [Abstract] [Full Text] [PDF] L. M. Morton, J. J. Turner, J. R. Cerhan, M. S. Linet, P. A. Treseler, C. A. Clarke, A. Jack, W. Cozen, M. Maynadie, J. J. Spinelli, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph) Blood, July 15, 2007; 110(2): 695 - 708. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020